The IQVIA white paper analyzes how small changes to R\&D performance levers can significantly improve pharmaceutical productivity and reduce cost per new product approval. Using a company-specific model, it shows how improvements in cycle times and success rates yield major cost savings, even for firms already performing well. Case studies from Pfizer, Lilly, and AstraZeneca demonstrate successful transformations driven by better governance, portfolio focus, and process optimization. Proactive, systematic reviews of R\&D levers can enable companies to enhance productivity before hitting critical lows and attract stronger returns on investment.

Join for free to read